Paritaprevir in patients with chronic hepatitis C genotype 1

摘要: ABSTRACT  Chronic hepatitis C is found worldwide. According to the WHO, it affects approximately 184 million patients around globe. For past decade, standard-of-care treatment of chronic consisted IFN-based regimens. However, IFN has its own limitations and not always well tolerated in all patients. In addition, yields unsatisfactory rates virologic response especially difficult-to-treat genotype 1 Recent scientific advances led development new IFN-free antiviral agents that are more effective, better with shorter duration. An all-oral regimen (paritaprevir/ritonavir ombitasvir, copackaged dasabuvir) recently received US FDA approval European Commission marketing authorizations for infection, including those cirrhosis. this article, we sought review pharmacokinetics, clinical efficacy side-effect profile pertaining parit...